Risk factors of proteinuria and potentially protective effect of renin –angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib
ConclusionIn patients with RCC receiving axitinib, pre-existing proteinuria and non-RAS inhibitor use were significantly associated with grade ≥ 2 proteinuria development. Our preliminary data should be confirmed by further studies.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Drugs & Pharmacology | Kidney Cancer | Proteinuria | Renal Cell Carcinoma | Study